Forty Seven
Advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways.
Employees
Enterprise value
$4.9b
loading funding rounds…
Wellington Management(exited)
Clarus Ventures(exited)
Lightspeed Venture Partners(exited)
Sutter Hill Ventures(exited)
GV(exited)
Gilead Sciences(exited)
| EUR | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.